Myriad Genetics, Inc. MYGN recently announced a collaboration with OptraHEALTH with the aim of implementing a cognitive ChatBOT, Gene. The AI-powered ChatBOT will provide genetic and financial assistance information to prospective patients of hereditary cancer.
Notably, the Gene knowledge platform, which is a Health Insurance Portability and Accountability Act compliant, has a BOT interface and can answer a variety of health-related questions about hereditary cancer. The ChatBOT interfaces with Myriad’s online hereditary cancer quiz.
Myriad Genetics is currently planning to launch the Gene ChatBOT for its Foresight and Prequel prenatal tests and for companion diagnostic testing in oncology in the latter half of 2020.
With the recent partnership, Myriad Genetics aims to boost its oncology portfolio on a global scale. This portfolio includes various molecular diagnostic tests, all of which comprise the broader Molecular Diagnostic Testing business.
More on Gene
The ChatBOT Gene is designed to automate a pre-test process